Skip to main
DGX
DGX logo

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 27 analyst ratings
Buy
Strong Buy 26%
Buy 19%
Hold 48%
Sell 4%
Strong Sell 4%

Bulls say

Quest Diagnostics Inc. demonstrates a strong financial outlook driven by robust growth in consumer-initiated testing, which saw revenue increases of nearly 50% in the fourth quarter and approximately 40% for the full fiscal year 2024. The company reported total revenue of $2.62 billion, reflecting a year-over-year increase of 14.5%, supported by a 13.9% rise in volumes. With expectations for expanding operating margins in 2025 and a strong cash flow from operations guidance of $1.45 billion, Quest Diagnostics is well-positioned for sustainable growth, bolstered by advancements in automation and AI initiatives that enhance operational efficiency.

Bears say

Quest Diagnostics Inc. faces significant financial challenges, primarily due to a projected headwind of approximately $0.20 per share related to investments in modernizing its IT infrastructure and compliance preparations for Laboratory Developed Testing (LDT) regulations. Additionally, the company is experiencing an anticipated $0.50 per share impact from higher year-over-year interest expenses, which further strains profitability. These factors, coupled with an uncertain hospital backdrop affecting reference test demand, contribute to a negative outlook for Quest Diagnostics’s stock.

Quest Diagnostics (DGX) has been analyzed by 27 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 19% recommend Buy, 48% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Buy based on their latest research and market trends.

According to 27 analysts, Quest Diagnostics (DGX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.